

Supplemental Table 1: FGFRi pre-treated patients with kinase domain resistance mutations identified in centrally tested ctDNA

Tumor Type	Cholangiocarcinoma	Cholangiocarcinoma	Cholangiocarcinoma	Gastric
Primary Driver	FGFR2-BICC1 Fusion	FGFR2-INA Fusion	FGFR2-BICC1 Fusion	FGFR2-CTNNB1 Fusion
Resistance	FGFR2 p.E565K FGFR2 p.V564F FGFR2 p.E565G FGFR2 p.N549H FGFR2 p.V564I FGFR2 p.T635I FGFR2 p.K641R	FGFR2 p.N549K FGFR2 p.V564F FGFR2 p.M537_M538delinsL FGFR2 p.N549H FGFR2 p.M537I	FGFR2 p.L617F (c.1851G>T) FGFR2 p.L617F (c.1851G>C) FGFR2 p.V564I FGFR2 p.M537I (c.1611G>T) FGFR2 p.M537I (c.1611G>A) FGFR2 p.M537I (c.1611G>C) FGFR2 p.N549K (c.1647T>A) FGFR2 p.N549K (c.1647T>G) FGFR2 p.I548N	FGFR2 p.L617M FGFR2 p.L617F